Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept, Inc. Announces Closing of Initial Public Offering
SAN DIEGO, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today the closing of its previously announced initial public offering of 1,900,000 shares of common stock, at a public offering
View HTML
Toggle Summary Biocept, Inc. Announces Pricing of Initial Public Offering
SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc., an oncology diagnostics company focused on improving individual patient treatment, today announced the pricing of its initial public offering of 1,900,000 shares of its common stock offered at a price to the public of $10.00 per share.
View HTML
Toggle Summary Biocept Expands Board of Directors with Two Distinguished Appointments
Dr. Marsha A. Chandler and Bruce A. Huebner Bring Life Sciences Relationships
View HTML
Toggle Summary Biocept Appoints Michael Nall as CEO
Biocept Appoints Michael Nall as CEO Biocept, Inc. announced today that it has appointed Michael W. Nall as President and Chief Executive Officer. Mr. Nall’s extensive commercialization, sales and marketing experience will be a significant asset as the company brings its pipeline of OncoCEETM
View HTML
Toggle Summary MD Anderson Cancer Center and Biocept, Inc. Study Reveals HER2+ CTCs and DTCs in Patients with HER2- Tumors by Tissue Analysis
MD Anderson Cancer Center and Biocept, Inc. Study Reveals HER2+ CTCs and DTCs in Patients with HER2- Tumors by Tissue Analysis San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) and
View HTML
Toggle Summary Biocept to Present Clinical Findings on Circulating Tumor Cells (CTCs) at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting
Biocept to Present Clinical Findings on Circulating Tumor Cells (CTCs) at the 2012 American Society for Clinical Oncology (ASCO) Annual Meeting San Diego, California – Biocept, Inc., a CLIA-certified laboratory testing company focused on oncology diagnostics, specifically the detection and analysis
View HTML
Toggle Summary Biocept to Present at the 103rd AACR Annual Meeting on New Analytic Methods for Circulating Tumor Cell Analysis, Including SelectorTM, Ultra-Sensitive Mutation Detection Technology
Biocept to Present at the 103rd AACR Annual Meeting on New Analytic Methods for Circulating Tumor Cell Analysis, Including SelectorTM, Ultra-Sensitive Mutation Detection Technology San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on
View HTML
Toggle Summary Biocept to present at Molecular Tri-Conference on Circulating Tumor Cells (CTCs)
Biocept to present at Molecular Tri-Conference on Circulating Tumor Cells (CTCs) San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that two of its
View HTML
Toggle Summary Clarient, Inc., a GE company, announces the launch of Biocept’s proprietary Circulating Tumor Cells (CTC) test for HER2 status in breast cancer patient
Clarient, Inc., a GE company, announces the launch of Biocept’s proprietary Circulating Tumor Cells (CTC) test for HER2 status in breast cancer patient San Diego and Aliso Viejo, California: – Biocept, Inc., a privately-held laboratory services company focused on Circulating Tumor Cells (CTCs), and
View HTML
Toggle Summary Biocept, Inc. Announces New Methods for Isolating Previously Unrecognized Circulating Tumor Cells (CTCs)
Biocept, Inc. Announces New Methods for Isolating Previously Unrecognized Circulating Tumor Cells (CTCs) San Diego, California – Biocept, Inc., a privately?held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells in cancer patients, announced
View HTML